IL230510A0 - Anti-Lyft peptides and their use in methods for treating diseases and disorders characterized by Lyft - Google Patents

Anti-Lyft peptides and their use in methods for treating diseases and disorders characterized by Lyft

Info

Publication number
IL230510A0
IL230510A0 IL230510A IL23051014A IL230510A0 IL 230510 A0 IL230510 A0 IL 230510A0 IL 230510 A IL230510 A IL 230510A IL 23051014 A IL23051014 A IL 23051014A IL 230510 A0 IL230510 A0 IL 230510A0
Authority
IL
Israel
Prior art keywords
fibrosis
methods
treating diseases
disorders characterized
fibrotic
Prior art date
Application number
IL230510A
Other languages
English (en)
Hebrew (he)
Original Assignee
Thrasos Innovation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrasos Innovation Inc filed Critical Thrasos Innovation Inc
Publication of IL230510A0 publication Critical patent/IL230510A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1875Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/51Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL230510A 2011-07-19 2014-01-16 Anti-Lyft peptides and their use in methods for treating diseases and disorders characterized by Lyft IL230510A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161509340P 2011-07-19 2011-07-19
US201261662337P 2012-06-20 2012-06-20
PCT/US2012/047468 WO2013013085A2 (en) 2011-07-19 2012-07-19 Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis

Publications (1)

Publication Number Publication Date
IL230510A0 true IL230510A0 (en) 2014-03-31

Family

ID=47558730

Family Applications (1)

Application Number Title Priority Date Filing Date
IL230510A IL230510A0 (en) 2011-07-19 2014-01-16 Anti-Lyft peptides and their use in methods for treating diseases and disorders characterized by Lyft

Country Status (11)

Country Link
US (2) US20140057831A1 (https=)
EP (1) EP2734220A4 (https=)
JP (1) JP2014527040A (https=)
CN (2) CN106478776A (https=)
AU (1) AU2012283924A1 (https=)
BR (1) BR112014001268A2 (https=)
CA (1) CA2842330A1 (https=)
HK (1) HK1198333A1 (https=)
IL (1) IL230510A0 (https=)
RU (1) RU2014105513A (https=)
WO (1) WO2013013085A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170232276A1 (en) * 2014-09-30 2017-08-17 Primegen Biotech, Llc Treatment of fibrosis using deep tissue heating and stem cell therapy
WO2016077539A1 (en) * 2014-11-12 2016-05-19 Thrasos Innovation, Inc. Peptides with enhanced stability and their use in methods for treating diseases
EP3289073A4 (en) * 2015-05-01 2019-07-17 University of Miami METHOD AND COMPOSITIONS FOR THE CONVERSION OF NON-ENDOCRINE PANCREATIC TISSUE IN INSULIN-PRODUCING CELLS
AU2016260190A1 (en) * 2015-05-12 2017-11-23 The Regents Of The University Of California Peptide treatment for inflammation and fibrosis
CN115925878A (zh) * 2015-06-05 2023-04-07 艾比欧公司 用于治疗纤维化的内皮抑素片段和变体
WO2019133950A1 (en) * 2017-12-30 2019-07-04 The Regents Of The University Of Colorado, A Body Corporate Smad7 for treatment and prevention of posterior capsule opacification
ES2906715T3 (es) * 2018-09-06 2022-04-20 Marine Essence Biosciences Corp Of Usa Dispositivos de biomaterial para la regeneración de tejidos guiada
US11361161B2 (en) * 2018-10-22 2022-06-14 Verint Americas Inc. Automated system and method to prioritize language model and ontology expansion and pruning
EP3996736A4 (en) * 2019-07-10 2023-05-24 Musc Foundation for Research Development ENDOSTATIN PEPTIDES FOR THE TREATMENT OF TUMOR, FIBROSIS AND ACUTE LUNG INJURY
CN111704653B (zh) * 2020-06-08 2023-10-03 深圳市图微安创科技开发有限公司 靶向于纤连蛋白衍生肽的抑制剂多肽化合物及其用途
CA3212468A1 (en) * 2021-03-16 2022-09-22 William D. Carlson Therapeutic combinations of tdfrps and additional agents and methods of use for the reversal of fibrosis
CN113069531B (zh) * 2021-04-09 2023-02-28 南开大学 一种防疤痕皮肤创伤修复用水凝胶及其制备方法
CN116768974A (zh) * 2022-03-11 2023-09-19 中山大学 用于预防和/或治疗肾纤维化的多肽化合物
WO2024081245A1 (en) 2022-10-10 2024-04-18 Therapeutics By Design, LLC Tissue differentiation factor related polypeptides (tdfrps) for the treatment of myocardial injury

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0894004B2 (en) * 1996-03-22 2007-02-21 Curis, Inc. Method for enhancing functional recovery of motor coordination, speech or sensory perception after central nervous system ischemia or trauma
WO2003106656A2 (en) * 2002-06-17 2003-12-24 Thrasos, Inc. Single domain tdf-related compounds and analogs thereof
US8410246B2 (en) * 2004-06-17 2013-04-02 Thrasos, Inc. TDF-related compounds and analogs thereof
DK2497780T3 (en) * 2005-09-20 2015-06-01 Thrasos Innovation Inc TDF-related compounds and analogs thereof
US20110275574A1 (en) * 2009-01-16 2011-11-10 Agency For Science, Technology And Research Method of inhibiting proliferation of hepatic stellate cells
WO2010099363A1 (en) * 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010128158A1 (en) * 2009-05-08 2010-11-11 Novartis Ag Diagnostic biomarkers for fibrotic disorders

Also Published As

Publication number Publication date
CN103890003A (zh) 2014-06-25
JP2014527040A (ja) 2014-10-09
BR112014001268A2 (pt) 2017-02-21
CN103890003B (zh) 2016-08-24
CA2842330A1 (en) 2013-01-24
HK1198333A1 (zh) 2015-04-02
WO2013013085A2 (en) 2013-01-24
EP2734220A4 (en) 2015-01-21
WO2013013085A3 (en) 2014-03-13
US20140057831A1 (en) 2014-02-27
AU2012283924A1 (en) 2014-02-06
EP2734220A2 (en) 2014-05-28
RU2014105513A (ru) 2015-08-27
CN106478776A (zh) 2017-03-08
US20160058829A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
IL230510A0 (en) Anti-Lyft peptides and their use in methods for treating diseases and disorders characterized by Lyft
IL229257A0 (en) Preparations and methods for the treatment of diseases related to the retina of the eye
ZA201401700B (en) Fusion proteins for treating metabolic disorders
EP2677986A4 (en) MOBILE THERAPEUTIC DEVICE AND METHOD THEREFOR
PT2717692T (pt) Ácidos tetra-hidrocanabinol-11-oicos para utilização no tratamento de doenças fibróticas
IL229541B (en) Petridine compounds and their uses for the treatment of autoimmune diseases
PL2938740T3 (pl) Chimeryczne peptydy fgf19 do zastosowania w leczeniu zaburzeń gospodarki kwasami żółciowymi
ZA201400562B (en) Axmi205 variant proteins and methods for their use
SG10201913930UA (en) Therapeutic nuclease compositions and methods
IL229226A0 (en) Pirfenidone and anti-fibrotic treatment in selected patients
IL230957B (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
IL232710A0 (en) l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders
IL231157A0 (en) Preparations and methods for the treatment of neurodegenerative diseases
IL231158A0 (en) Preparations and methods for the treatment of neurodegenerative diseases
PL2726470T3 (pl) Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych
GB201107396D0 (en) Improvements in methods and apparatus for use in the manufacture of innerspring assemblies
SG11201402899TA (en) Methods and compositions for treating viral diseases
HUE039105T2 (hu) Kalcitonin mimetikumok betegségek és rendellenességek kezelésére
EP2877577A4 (en) ELECTROPORATED AMPHIBIENOO CYTS ISOLATED EXTRACTS AND THEIR USE FOR THE TREATMENT OF ILLNESSES AND DISORDERS
GB201117876D0 (en) Peptides and their use in treatment
IL227818A0 (en) A flexible therapeutic device and a method for using it
IL245613A0 (en) Peptides for use in the treatment of inflammatory diseases that are not related to pathogenic factors
HK1196941A (en) The neurotrophic factors manf and cdnf for use in the treatment of retinal disorders
EP2747765A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES
HK1179853A (en) Aptamers to 4-1bb and their use in treating diseases and disorders